Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors

Xenobiotica

Volumn 44, Issue 5, 2014, Pages 404-416

  Zhang, Yan Yan ^a   Liu, Yong ^a   Mehboob, Shahila ^a   Song, Jin Hua ^b,c   Boci, Teuta ^a   Johnson, Michael E ^a   Ghosh, Arun K ^b,c   Jeong, Hyunyoung ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Center for Pharmaceutical Biotechnology University of Illinois at Chicago ^*  (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Antibiotics; Metabolism; Microsome; Optimization

Indexed keywords

BENZIMIDAZOLE; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; FRANCISELLA TULARENSIS ENOYL REDUCTASE INHIBITOR; N BENZYL BENZIMIDAZOLE; OXACYCLOPENTANE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; FRANCISELLA TULARENSIS; IC 50; LIVER CLEARANCE; LIVER MICROSOME; METABOLITE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; POLARIZATION; PREDICTION; QUANTITATIVE STRUCTURE PROPERTY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; ENZYMOLOGY; METABOLISM; PRECLINICAL STUDY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; BLOOD PROTEINS; DRUG EVALUATION, PRECLINICAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; FEMALE; FRANCISELLA TULARENSIS; MICE; MICE, INBRED BALB C; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898735797     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.850553     Document Type: Article

References (36)

1. Boyer D, Bauman JN, Walker DP, et al. (2009). Utility of metaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl- 1H-indol-3-yl)-N-phenethyl-ace tamide. Drug Metab Dispos 37:999-1008.
2. Bush K, Pucci MJ. (2011). New antimicrobial agents on the horizon. Biochem Pharmacol 82:1528-39.
3. Chiba M, Ishii Y, Sugiyama Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-76.
4. Davies B, Morris T. (1993). Physiological-parameters in laboratoryanimals and humans. Pharm Res 10:1093-5.
5. de Oliveira DB, Gaudio AC. (2001). BuildQSAR: a new computer program for QSAR analysis. Quant Struct-Act Relat 19:599-601.
6. Di L, Keefer C, Scott DO, et al. (2012). Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57: 441-8.
7. Di L, Kerns EH, Li SQ, et al. (2006). High throughput microsomal stability assay for insoluble compounds. Int J Pharm 317:54-60.
8. Golbraikh A, Tropsha A. (2002). Beware of q(2)! J Mol Graph Model 20: 269-76.
9. Gupta RR, Gifford EM, Liston T, et al. (2010). Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos 38:2083-90.
10. Hagan MT, Menhaj MB. (1994). Training feedforward networks with the marquardt algorithm. IEEE Trans Neural Netw 5:989-93.
11. Hepburn MJ, Simpson AJH. (2008). Tularemia: current diagnosis and treatment options. Expert Rev Anti-Infect Ther 6:231-40.
12. Hernandes MZ, Cavalcanti SMT, Moreira DRM, et al. (2010). Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets 11:303-14.
13. Hernandez-Covarrubias C, Vilchis-Reyes MA, Yepez-Mulia L, et al. (2012). Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives. Eur J Med Chem 52:193-204.
14. Hevener KE, Mehboob S, Su PC, et al. (2012). Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. J Med Chem 55:268-79.
15. Hu YB, Unwalla R, Denny RA, et al. (2010). Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability. J Comput-Aided Mol Des 24:23-35.
16. Jeong H, Chiou WL. (2006). Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 36:1-13.
17. Kirchmair J, Williamson MJ, Tyzack JD, et al. (2012). Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inform Model 52:617-48.
18. Kreuzer PE, Kessler W, Welter HF, et al. (1991). Enzyme specific kinetics of 1,2-epoxybutene-3 in microsomes and cytosol from livers of mouse, rat, and man. Arch Toxicol 65:59-67.
19. Leonard JT, Roy K. (2006). On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 25: 235-51.
20. Meanwell NA. (2011). Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24:1420-56.
21. Mehboob S, Hevener KE, Truong K, et al. (2012). Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors. J Med Chem 55:5933-41.
22. Norinder U, Bergstrom CAS. (2006). Prediction of ADMET properties. ChemMedChem 1:920-37.
23. Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-9.
24. Oyston PCF, Sjostedt A, Titball RW. (2004). Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol 2:967-78.
25. Palani A, Shapiro S, Josien H, et al. (2002). Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1.Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem 45:3143-60.
26. Platts JA, Butina D, Abraham MH, et al. (1999). Estimation of molecular linear free energy relation descriptors using a group contribution approach. J Chem Inform Comput Sci 39:835-45.
27. Pohanka M, Skladal P. (2009). Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents-review. Folia Microbiol 54:263-72.
28. Sahua K, Siddiqui AA, Shaharyara M, et al. (2013). Chromatographic separation of piracetam and its metabolite in a mixture of microsomal preparations, followed by an MS/MS analysis. Eur J Med Chem 65: 94-101.
29. Sakiyama Y, Yuki H, Moriya T, et al. (2008). Predicting human liver microsomal stability with machine learning techniques. J Mol Graph Model 26:907-15.
30. Sharma V, Goswami R, Madan AK. (1997). Eccentric connectivity index: a novel highly discriminating topological descriptor for structure-property and structure-activity studies. J Chem Inform Comput Sci 37:273-82.
31. Stepan AF, Karki K, McDonald WS, et al. (2011). Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as gammasecretase inhibitors. J Med Chem 54:7772-83.
32. Todeschini R, Gramatica P. (1998). New 3D molecular descriptors: the WHIM theory and QSAR applications. Perspect Drug Discov Design 9-11:355-80.
33. Vacondio F, Silva C, Lodola A, et al. (2011). Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. Eur J Med Chem 46:4466-73.
34. Wen L, Chmielowski JN, Bohn KC, et al. (2009). Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets. Protein Expr Purif 65:83-91.
35. Wright HT, Reynolds KA. (2007). Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 10:447-53.
36. Yap CW. (2011). PaDEL-Descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32:1466-74.